Filgotinib for moderately to severely active ulcerative colitis.
Fiche publication
Date publication
octobre 2022
Journal
Expert review of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Mannucci A, D'Amico F, El Saadi A, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.
Mots clés
JAK inhibitor, inflammatory bowel diseases, selective, small molecule, ulcerative colitis
Référence
Expert Rev Gastroenterol Hepatol. 2022 10 24;: